Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression

Cellular and Molecular Immunology

Volumn 14, Issue 10, 2017, Pages 819-829

  Zhang, Qiong Fang ^a   Yin, Wen Wei ^a   Xia, Yang ^a   Yi, Ya Yang ^a   He, Qiu Feng ^a   Wang, Xing ^a   Ren, Hong ^a   Zhang, Da Zhi ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

CD11b; CD27; dysfunction; NK; subsets

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; CD11B ANTIGEN; CD27 ANTIGEN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; LIVER CELL CARCINOMA; LIVER INFILTRATING CD11B- CD27- NATURAL KILLER CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MALE; NATURAL KILLER CELL; PHENOTYPE; PROTEIN EXPRESSION; SURVIVAL TIME; CARCINOGENESIS; CASE CONTROL STUDY; CELL SEPARATION; FLOW CYTOMETRY; FOLLOW UP; HOMEOSTASIS; IMMUNOLOGY; IMMUNOPHENOTYPING; LIVER; LIVER TUMOR; LYMPHOCYTE SUBPOPULATION; METABOLISM; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS;

ADULT; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CD11B ANTIGEN; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HOMEOSTASIS; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LIVER; LIVER NEOPLASMS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 7;

EID: 85031297027     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2016.28     Document Type: Article

References (82)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
2. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-2063.
3. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215-219.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. Cancer J Clin 2007; 57: 43-66.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
6. Screpanti V, Wallin RP, Grandien A, Ljunggren HG. Impact of FASLinduced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 2005; 42: 495-499.
7. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of naturalkiller-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-861.
8. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003; 90: 127-156.
9. Guimaraes F, Guven H, Donati D, Christensson B, Ljunggren HG, Bejarano MT et al. Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice. Leukemia 2006; 20: 833-839.
10. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
11. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35: 23-28.
12. Bruno A, Ferlazzo G, Albini A, Noonan DM. A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst 2014; 106: dju200.
13. Nishida S, Levi DM, Tzakis AG. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma. Curr Opin Organ Transplant 2013; 18: 690-694.
14. Li F, Tian Z. The liver works as a school to educate regulatory immune cells. Cell Mol Immunol 2013; 10: 292-302.
15. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013; 19: 859-868.
16. Han Q, Zhang C, Zhang J, Tian Z. The role of innate immunity in HBV infection. Semin Immunopathol 2013; 35: 23-38.
17. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol 2003; 3: 413-425.
18. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006; 203: 1033-1043.
19. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640.
20. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101: 3052-3057.
21. Brodin P, Karre K, Hoglund P. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol 2009; 30: 143-149.
22. Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010; 116: 3865-3874.
23. Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park I-K et al. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 2010; 115: 274-281.
24. Ndhlovu LC, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012; 119: 3734-3743.
25. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood 2009; 113: 5488-5496.
26. Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ. Functional subsets of mouse natural killer cells. Immunol Rev 2006; 214: 47-55.
27. Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology 2011; 133: 350-359.
28. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121: 3609-3622.
29. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A 2005; 102: 2886-2891.
30. Song, do S, Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol 2012; 18: 258-267.
31. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
32. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-2063.
33. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215-219.
34. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. Cancer J Clin 2007; 57: 43-66.
35. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
36. Screpanti V, Wallin RP, Grandien A, Ljunggren HG. Impact of FASLinduced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 2005; 42: 495-499.
37. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of naturalkiller-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-861.
38. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003; 90: 127-156.
39. Guimaraes F, Guven H, Donati D, Christensson B, Ljunggren HG, Bejarano MT et al. Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice. Leukemia 2006; 20: 833-839.
40. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
41. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35: 23-28.
42. Bruno A, Ferlazzo G, Albini A, Noonan DM. A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst 2014; 106: dju200.
43. Nishida S, Levi DM, Tzakis AG. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma. Curr Opin Organ Transplant 2013; 18: 690-694.
44. Li F, Tian Z. The liver works as a school to educate regulatory immune cells. Cell Mol Immunol 2013; 10: 292-302.
45. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013; 19: 859-868.
46. Han Q, Zhang C, Zhang J, Tian Z. The role of innate immunity in HBV infection. Semin Immunopathol 2013; 35: 23-38.
47. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol 2003; 3: 413-425.
48. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006; 203: 1033-1043.
49. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640.
50. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101: 3052-3057.
51. Brodin P, Karre K, Hoglund P. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol 2009; 30: 143-149.
52. Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010; 116: 3865-3874.
53. Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park I-K et al. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 2010; 115: 274-281.
54. Ndhlovu LC, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012; 119: 3734-3743.
55. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood 2009; 113: 5488-5496.
56. Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ. Functional subsets of mouse natural killer cells. Immunol Rev 2006; 214: 47-55.
57. Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology 2011; 133: 350-359.
58. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121: 3609-3622.
59. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A 2005; 102: 2886-2891.
60. Song, do S, Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol 2012; 18: 258-267.
61. Manini MA, Sangiovanni A, Fornari F, Piscaglia F, Biolato M, Fanigliulo L et al. Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. J Hepatol 2014; 60: 995-1001.
62. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
63. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
64. Rehermann B, Naoumov NV. Immunological techniques in viral hepatitis. J Hepatol 2007; 46: 508-520.
65. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78.
66. Cheung PF, Yip CW, Ng LW, Wong CK, Cheung TT, Lo CM et al. Restoration of natural killer activity in hepatocellular carcinoma by treatment with antibody against granulin-epithelin precursor. Oncoimmunology 2015; 4: e1016706.
67. Zhou Z, Yu X, Zhang J, Tian Z, Zhang C. TLR7/8 agonists promote NKDC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett 2015; 369: 298-306.
68. Sun C, Sun HY, Xiao WH, Zhang C, Tian ZG. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin 2015; 36: 1191-1199.
69. Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol 2015; 12: 292-302.
70. Zhang P, Lu X, Tao K, Shi L, Li W, Wang G et al. Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma. J Surg Res 2015; 194: 107-113.
71. Mattiola I, Pesant M, Tentorio PF, Molgora M, Marcenaro E, Lugli E et al. Priming of human resting NK cells by autologous M1 macrophages via the engagement of IL-1beta. IFN-beta, and IL-15 Pathways 2015; 195: 2818-2828.
72. Joncker NT, Shifrin N, Delebecque F, Raulet DH. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med 2010; 207: 2065-2072.
73. + T cells antagonizes T cell surveillance of tumor development. Oncoimmunology 2012; 1: 162-171.
74. Salazar-Onfray F, López MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007; 18: 171-182.
75. Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2004; 172: 464-474.
76. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011; 71: 5412-5422.
77. Caligiuri MA. Human natural killer cells. Blood 2008; 112: 461-469.
78. Fu B, Tian Z, Wei H. Subsets of human natural killer cells and their regulatory effects. Immunology 2014; 141: 483-489.
79. Cariani E, Pilli M, Zerbini A, Rota C, Olivani A, Pelosi G et al. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One 2012; 7: e32493.
80. Gao Q, Zhou J, Wang XY, Qiu SJ, Song K, Huang XW, et al. Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 455-466.
81. Cai XY, Wang JX, Yi Y, He HW, Ni XC, Zhou J et al. Low counts of gammadelta T cells in peritumoral liver tissue are related to more frequent recurrence in patients with hepatocellular carcinoma after curative resection. Asian Pacific J Cancer Prev 2014; 15: 775-780.
82. Ramzan M, Sturm N, Decaens T, Bioulac-Sage P, Bancel B, Merle P et al. Liver-infiltrating CD8 lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma. Liver Int 2015; 36: 434-444.